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Myocardial injury is increased in the aged heart following ischemia-reperfusion (ISC-REP) compared to adult hearts. Intervention
at REP with ischemic postconditioning decreases injury in the adult heart by attenuating mitochondrial driven cell injury. Unfortunately, postconditioning is ineﬀective in aged hearts. Blockade of electron transport at the onset of REP with the reversible inhibitor
amobarbital (AMO) decreases injury in adult hearts. We tested if AMO treatment at REP protects the aged heart via preservation of
mitochondrial integrity. Buﬀer-perfused elderly Fischer 344 24 mo. rat hearts underwent 25 min global ISC and 30 min REP. AMO
(2.5 mM) or vehicle was given for 3 min at the onset of REP. Subsarcolemmal (SSM) and interfibrillar (IFM) mitochondria were
isolated after REP. Oxidative phosphorylation (OXPHOS) and mitochondrial inner membrane potential were measured. AMO
treatment at REP decreased cardiac injury. Compared to untreated ISC-REP, AMO improved inner membrane potential in SSM
and IFM during REP, indicating preserved inner membrane integrity. Thus, direct pharmacologic modulation of electron transport at REP protects mitochondria and decreases cardiac injury in the aged heart, even when signaling-induced pathways of postconditioning that are upstream of mitochondria are ineﬀective.

1. Introduction
The aged heart sustains increased injury during ischemiareperfusion in both experimental models [1–4] and in elderly
patients [5]. Aging hearts are also resistant to the powerful
endogenous protections provided by ischemic preconditioning and postconditioning [6–12]. Pharmacological conditioning such as anesthetic preconditioning also does not protect the aging heart during ischemia-reperfusion [13]. Aging
causes dysfunction in interfibrillar mitochondria [14]. The
aging defect in complex III and cytochrome oxidase decreases oxidative phosphorylation and increases the generation of reactive oxygen species [14–16]. Improvement of ageinduced mitochondrial dysfunction with supplementation of
acetylcarnitine decreases myocardial injury during ischemiareperfusion [17], supporting that the electron transport

chain defects present in the aged heart contribute to the
increased myocardial injury.
Cardiac ischemia damages the electron transport chain
and leads to the increased generation of reactive oxygen species (ROS) and mitochondrial calcium over load [18–22].
Opening of the mitochondrial permeability transition pore
(MPTP) is a critical step in the onset of cardiomyocyte death
[23, 24]. The increased generation of ROS and calcium overload are key factors that induce MPTP opening during cellular stress [25–28]. Although the increased production of ROS
and calcium overload occur during ischemia [18], MPTP
opening occurs mostly during reperfusion. Ischemia induces
intracellular acidification that blunts MPTP opening [25–
28]. Ischemic postconditioning decreases cardiac injury and
prevents MPTP opening in adult hearts [21], supporting that
MPTP mainly opens during reperfusion. Postconditioning
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leads to activation of cytoprotective signaling cascades,
including the reperfusion injury salvage kinase pathway cascade (RISK) [29] and the tumor necrosis factor-STAT3
cascade (SAFE) [30]. Intervention during early reperfusion is
still able to reduce cardiac injury although ischemic damage
to the electron transport chain has already occurred [21, 31].
In fact, in the adult heart, postconditioning appears to work
via protection against MPTP in mitochondria that have sustained damage from ischemia [32]. Unfortunately, ischemic
postconditioning does not protect aged myocardium [6, 33,
34]. Alternative approaches must be found to decrease cardiac injury in the aged heart.
Blockade of electron transport with amobarbital during ischemia protects cardiac mitochondria and decreases
myocardial injury in adult hearts [18, 19, 35]. Amobarbital
given before ischemia also decreases cardiac injury in aged rat
hearts measured after reperfusion [36]. These findings suggest that direct manipulation of mitochondrial function is an
alternative approach to protect aged hearts that lack eﬀective
endogenous cytoprotective mechanisms.
Although prevention of mitochondrial damage during
ischemia by amobarbital treatment [18, 19, 35] or ischemic
preconditioning [6–8, 34] is an optimal strategy for cardioprotection, the clinical relevance of these treatments is limited due to the unpredictable occurrence of ischemic events.
Interventions applied at the onset of reperfusion are practical
for therapeutic use in the treatment of acute myocardial
infarction [21, 37]. Direct blockade of electron transport by
amobarbital at the onset of reperfusion decreases myocardial
injury in the adult heart [19, 31]. In the present study, we
tested if blockade of electron transport at the onset of reperfusion was able to decrease cardiac injury in the aged heart.
We also evaluated if protection by direct modulation of mitochondrial function during early reperfusion is mediated by
the protection of mitochondrial inner membrane integrity.
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10 min reperfusion. Coronary eﬄuent was collected during
the 30 min reperfusion period, and LDH activity in coronary
eﬄuent was determined to reflect myocardial injury [35].
2.3. Determination of Myocardial Infarct Size. In order to further evaluate the amobarbital-mediated cardiac protection,
myocardial infarct size was measured in buﬀer-perfused
mouse hearts in the absence and presence of amobarbital
treatment at the onset of reperfusion. In untreated hearts, the
heart was perfused for 15 min with K-H buﬀer, followed by
30 min global ischemia at 37◦ C and 60 min reperfusion [38].
In the amobarbital-treated group, hearts followed the same
perfusion protocol except that amobarbital was perfused in
identical K-H buﬀer for three min at onset of reperfusion
(Figure 1, lower panel) [35]. Hearts were paced at 420 beats
per min during the 15 min equilibration period and again
after 10 min reperfusion. Coronary eﬄuent was collected
during the 30 min reperfusion period, and LDH activity
in coronary eﬄuent was determined to reflect myocardial
injury [35]. Myocardial infarct size was determined using
TTC staining [35].
2.4. Mitochondrial Isolation and Functional Assessment. Subsarcolemmal (SSM) and interfibrillar (IFM) mitochondria
were isolated from hearts at the end of the experiment [35].
Oxidative phosphorylation was determined using a Clarktype oxygen electrode at 30◦ C [35]. H2 O2 production from
intact mitochondria was measured using the oxidation of the
fluorogenic indicator Amplex Red in the presence of horseradish peroxidase (HRP) [39].

2.1. Preparation of Rat Hearts for Perfusion. The Animal Care
and Use Committees of the McGuire VA Medical Center and
Virginia Commonwealth University approved the protocol.
Male Fischer rats (24 mo.) were anesthetized with pentobarbital sodium (100 mg/kg i.p.) and anticoagulated with heparin (1000 IU/kg i.p.). Hearts were excised and perfused retrograde via the aorta in the Langendorﬀ mode with modified
Krebs-Henseleit (K-H) buﬀer oxygenated with 95% O2 /5%
CO2 as previously described [35]. Cardiac function was
monitored with a balloon inserted into the left ventricle.

2.5. Measurement of Mitochondrial Inner Membrane Potential.
Mitochondrial inner membrane potential was assessed using
the fluorescence intensity of the indicator TMRM (tetramethylrhodamine, methyl ester) [40]. TMRM is a lipophilic
cation accumulated by mitochondria in proportion to Δψ
(emission at 590 nM, excitation at two wavelengths: 573 nm
and 546 nm). Accumulated TMRM in mitochondria causes a
fluorescence “red shift,” and fluorescence intensity was quantified by calculating the ratio of intensity from 573 to intensity from 546 (573/546). TMRM was selected to reflect membrane potential since TMRM did not inhibit oxidative phosphorylation at the concentration (0.3 μM) used [40]. The Δψ
was reflected by Δ change of fluorescence intensity of TMRM
in the presence of ADP (2 mM), oligomycin (1 μM), and
DNP (0.2 mM/each) using glutamate (10 mM) as a complex
I substrate (Figure 4).

2.2. Protocol for Heart Ischemia and Reperfusion and Amobarbital Perfusion. In untreated hearts, the heart was perfused
for 15 min with K-H buﬀer, followed by 25 min global
ischemia at 37◦ C and 30 min reperfusion. In the amobarbital
treated group, hearts followed the same perfusion protocol
except that amobarbital (2.5 mM) was perfused in identical
K-H buﬀer for three min at onset of reperfusion (Figure 1,
upper panel) [35]. Hearts were paced at 300 beats per min
during the 15 min equilibration period and again after

2.6. Determination of Calcium Tolerance Capacity (CRC).
Mitochondrial tolerance to calcium loading was studied in
the single-cell fluorometer using repetitive calcium pulses
[21, 41]. Freshly isolated SSM and IFM (0.2 mg/mL) were
incubated in buﬀer (150 mM sucrose, 50 mM KCl, 2 mM
KPi, and 20 mM Tris/HCl, pH 7.4) for 90 sec. with stirring at
30◦ C with 0.5 μM calcium green. Succinate (5 mM) was used
as substrate. Pulses of calcium (20 nmoles) were added at
1 min intervals. The number of pulses that resulted in

2. Methods
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Figure 1: Time course of ischemia and reperfusion. In the untreated rat heart group after 25 min global ischemia, the heart underwent
30 min reperfusion. In the amobarbital- (AMO-) treated group, the drug (2.5 mM) was given for three min at the onset of reperfusion
followed by 27 min of untreated Krebs-Henseleit buﬀer perfusion (upper panel). In isolated mouse hearts, hearts were subjected to 30 min
global ischemia and 60 min reperfusion with and without amobarbital treatment. The infarct size was determined at the end of reperfusion
(lower panel).

calcium release (MPTP opening) was used to calculate CRC
(Figure 6(a)).
2.7. Statistical Analysis. Data are expressed as the mean ±
standard error of the mean. Diﬀerences among groups were
compared by two-tailed t-test (SigmaStat 3.5, ProgramPaketet, Gothenburg, Sweden). Two-way ANOVA was used
to analyze the hemodynamic data and inner mitochondrial
membrane potential, and post hoc test was used to show
statistical diﬀerence between groups. A diﬀerence of P < 0.05
was considered significant.

3. Results
3.1. Reversible Blockade of Electron Transport at Onset of Reperfusion Decreased Myocardial Injury. There were no differences in hemodynamic data (left ventricular developed
pressure-LVDP and left ventricular end diastolic pressureLVEDP) between the two groups at the end of the equilibration period before ischemia (Figure 2). Ischemia markedly
increased diastolic pressure (LVEDP) in both groups
(Figure 2). There was no diﬀerence in LVEDP between the
two groups at the end of ischemia, indicating that hearts in
both groups suﬀered the same degree of ischemic contracture
before treatment. The diastolic pressure remained elevated
during reperfusion in untreated hearts. Amobarbital given
during early reperfusion had minimal eﬀect on diastolic
pressure (Figure 2). In untreated hearts, LVDP is markedly
decreased during reperfusion compared to the preischemic
value. Amobarbital given during reperfusion tended to improve the recovery of LVDP, but it did not reach statistical

significance (Figure 2). In contrast to cardiac function, amobarbital given at the onset of reperfusion markedly decreased
LDH release into coronary eﬄuent compared to untreated
hearts, indicating that modulation of electron transport
during early reperfusion provided solid cardioprotection in
aged hearts following reperfusion (Figure 3(a)). Amobarbital given during early reperfusion also protected buﬀerperfused mouse hearts as shown by decreased LDH release
(Figure 3(b)) and myocardial infarct size (Figure 3(c)). These
data further support that reversible blockade of electron
transport during early reperfusion decreased myocardial
injury.
3.2. Reversible Blockade of Electron Transport at the Onset of
Reperfusion Did Not Improve Mitochondrial Oxidative Phosphorylation. Amobarbital given during reperfusion did not
improve oxidative phosphorylation in SSM or IFM (glutamate, succinate, and TMPD-ascorbate as complex I, II, and
IV substrates, resp.) compared to untreated hearts (Table 1).
Amobarbital treatment also did not alter uncoupled respiration induced by dinitrophenol (DNP) compared to untreated
hearts (Table 1). Thus, manipulation of respiration during
early reperfusion did not protect the electron transport
chain. This result was consistent with our previous findings
that the damage to the electron transport chain occurred
during ischemia, rather than during reperfusion [21, 35, 42].
3.3. Reversible Blockade of Electron Transport at the Onset of
Reperfusion Improved Mitochondrial Inner Membrane Potential. Mitochondrial inner membrane potential was used to
assess inner membrane permeability during reperfusion. An
original tracing of inner membrane potential is shown in
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Table 1: Oxidative phosphorylation in SSM and IFM following
ischemia-reperfusion.

LVDP (mmHg)

125
100
75

SSM

∗

∗

ISC-REP AMO + REP
Glutamate-ADP 94 ± 10
109 ± 11
Glutamate-DNP 93 ± 9
114 ± 13
Succinate-ADP 100 ± 9
124 ± 10
Succinate-DNP 97 ± 9
119 ± 10
TMPD-ADP
408 ± 23
438 ± 16

50
25
0

EQ 15 min

REP 30 min
(a)

LVEDP (mmHg)

75

∗

∗

60

∗
∗

45
30
15
0

EQ 15 min

ISC 25 min

REP 30 min

ISC-REP
AMO + ISC-REP
(b)

Figure 2: Hemodynamic changes during ischemia and reperfusion.
There were no diﬀerences in left ventricular developed pressure
(LVDP) and diastolic pressure (LVEDP) between the two groups at
the end of the 15 min equilibration (EQ) period before ischemia.
The diastolic pressure in untreated hearts was not diﬀerent in the
two groups at the end of ischemia, prior to treatment. LVDP and
LVEDP were similar in both groups during reperfusion. (Mean ±
SEM; ∗ P < 0.05 versus preischemia value, n = 10 in each group.)

Figure 4. Mitochondrial inner membrane potential stimulated by ADP was significantly improved in both SSM and
IFM by amobarbital treatment compared to untreated hearts
(Figure 5). Amobarbital treatment improved inner membrane potential in the presence of oligomycin (complex V
inhibitor) in both SSM and IFM, suggesting that complex V
was not the site of the defect (Figure 5). Titration of DNP
caused complete depolarization of mitochondria (Figure 4).
Amobarbital treatment improved inner membrane potential
with DNP titration in both SSM and IFM (Figure 5).
3.4. Reversible Blockade of Electron Transport at Onset of
Reperfusion Did Not Improve Mitochondrial Calcium Retention Capacity (CRC). CRC was used to assess MPTP opening
in isolated mitochondria [21]. An original tracing of CRC
measurement is shown in Figure 6(a). Amobarbital treatment during reperfusion did not significantly improve CRC
in SSM and IFM compared to untreated hearts (Figure 6(b)).
3.5. Blockade of Electron Transport at the Onset of Reperfusion
Decreases H2 O2 Generation. Mitochondrial electron transport is a major source of ROS generation [22, 43]. Using
glutamate as a complex I substrate, amobarbital treatment

IFM
ISC-REP AMO + REP
123 ± 11
145 ± 14
121 ± 12
149 ± 15
127 ± 10
154 ± 13
121 ± 10
148 ± 13
488 ± 28
560 ± 36

Data are expressed as mean ± SEM; P = NS, ISC-REP versus AMO + REP,
N = 10 in each group.

decreased the generation of H2 O2 in SSM compared to untreated hearts (Figure 7). The amount of H2 O2 generated
from IFM from amobarbital treated hearts also was lower
than that in the untreated group (P = 0.051). There was
no diﬀerence in H2 O2 production between the two groups
in both SSM and IFM using succinate + rotenone as a complex II substrate (H2 O2 pmol/mg/min Mean ± SEM: SSM,
109 ± 5 untreated versus 96 ± 9 amobarbital; IFM, 111 ±
3 untreated versus 114 ± 8 amobarbital, P = NS, n = 5 in
each group).

4. Discussion
The novel findings of the present study are (1) reversible
blockade of electron transport at the onset of reperfusion
decreases myocardial injury in aged hearts; (2) the protection
by amobarbital treatment during reperfusion was mediated
by protection of the inner mitochondrial membrane. The
present study indicates that modulation of mitochondrial
respiration at the onset of reperfusion is able to decrease cardiac injury in the aged heart even when oxidative phosphorylation was already compromised from ischemia [42]. Thus,
the aged heart can be protected in a manner similar to the
adult heart by using this translationally relevant pharmacologic strategy to attenuate cardiac injury during reperfusion.
Aging leads to impaired mitochondrial function that
augments myocardial injury during ischemia-reperfusion
[15, 17, 42]. The loss of endogenous protective mechanisms
in the aged heart provides a greater challenge to protect
the aged heart during acute myocardial infarction and its
treatment. The endogenous protective mechanisms can be
restored in aging hearts by treatments such as caloric restriction [44], exercise [45], and a pharmacologic strategy to inhibit protein phosphatase 2A activity [46]. Supplementation of
acetylcarnitine before ischemia decreases myocardial injury
in aged hearts via restoration of mitochondrial respiration to
an adult-phenotype [17]. However, these approaches must
all be instituted before ischemia and require variable pretreatment periods in order to be eﬀective. Due to the unpredictable occurrence of acute ischemic events, these strategies are unfortunately less clinically relevant to protect
the ischemic-reperfused aged heart. In the present study,
amobarbital given at the onset of reperfusion decreased
myocardial injury. Compared to the pre-ischemia strategies,
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Figure 3: LDH release during reperfusion in isolated rat hearts (a). LDH activity in coronary eﬄuent during 30 min reperfusion was
measured in order to assess myocardial injury. Amobarbital given at the onset of reperfusion markedly decreased LDH release compared to
untreated hearts, supporting that the modulation of mitochondrial respiration during early reperfusion decreased myocardial injury in the
aged hearts. Amobarbital treatment also decreased LDH release in buﬀer perfused mouse hearts (b) and myocardial infarct size (c). (Mean ±
SEM; ∗ P < 0.05 versus untreated hearts n = 6–10 in each group.)

amobarbital treatment at reperfusion has therapeutic potential since amobarbital could be regionally infused during primary stent-mediated reperfusion treatment of ST elevation
acute infarcts in the high risk elderly patient population [5].
Amobarbital given before ischemia decreases cell injury
in isolated rabbit [19], rat [35, 47], and guinea pig hearts
[18]. Amobarbital given before ischemia prevents electron
transport chain damage measured following reperfusion in
isolated adult [35] and aged rat hearts [36]. In the present
study, amobarbital given at the onset of reperfusion does not
protect the electron transport chain in aged hearts. Taken
together, these results further support the notion that the
damage of mitochondrial electron transport chain mainly
occurs during ischemia, rather than during reperfusion [48],
including in the aged heart [49]. In the adult heart, amobarbital treatment during reperfusion decreases cardiac injury
without improving oxidative phosphorylation [31] indicating that the mechanism of myocyte death during reperfusion
is not solely dependent on the function of mitochondrial
respiration. Ischemic postconditioning, another well known
method applied during early reperfusion, also fails to improve oxidative phosphorylation in the adult heart [21,
50]. Thus, manipulation of ischemia-damaged mitochondria
either via activation of cytoprotective signaling systems in the
adult heart [29, 50–52] or this novel direct manipulation of
mitochondrial function in the aged heart is able to decrease
myocardial injury during reperfusion.
MPTP opening contributes to myocyte death during
ischemia-reperfusion [23, 24, 53]. Although the exact structure of the MPTP remains elusive, the eﬀect of MPTP
opening is clear: its opening leads to increased permeability

of both mitochondrial inner and outer membranes [23, 26].
Mitochondrial inner membrane potential (Ψ) is commonly
used to reflect the permeability of the inner membrane [25,
53], including from MPTP. In the present study, inner membrane potential was used to reflect inner membrane integrity
in isolated mitochondria. Amobarbital treatment preserves
inner membrane potential in both SSM and IFM compared
to untreated hearts, suggesting that amobarbital decreases
the permeability of inner membrane during reperfusion. In
the presence of oligomycin [54], inner membrane potential remains lower in mitochondria from untreated hearts
compared to amobarbital treatment, indicating that there
is a consistent proton leakage site other than complex V.
Ischemia-reperfusion may activate uncoupling proteins that
allow proton backflow into the matrix [54]. If this was the
case, we anticipate that the diﬀerence of Ψ between untreated
and amobarbital-treated mitochondria would be eliminated
in the presence of uncoupler, DNP. Amobarbital improves
inner membrane potential in the presence of DNP, suggesting
that uncoupling proteins are a less likely mechanism for
the proton leak. Another potential proton leak site is the
adenine nucleotide translocase (ANT) [54]. ANT was once
considered a key component of the MPTP, but the role of
ANT in the pore is now uncertain [55]. We found that inhibition of ANT using bongkrekic acid did not restore inner
membrane potential in mitochondria following ischemiareperfusion (data not shown). These results indicate that the
impairment of inner membrane potential in mitochondria
isolated following ischemia-reperfusion in the aged heart is
not through the specific sites discussed above.
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Figure 4: Measurement of mitochondrial inner membrane potential. The upper panel is an original tracing of an inner membrane
potential measurement. Glutamate (10 mM) was used as a complex I substrate to polarize the inner membrane potential. ADP
stimulated the depolarization of inner membrane potential. Inner
membrane potential was restored when oligomycin was used to
inhibit complex V. Dinitrophenol (DNP) was titrated to completely
collapse inner membrane potential. The Δ change of fluorescence
intensity was used to assess inner mitochondrial membrane potential in the presence of ADP, oligomycin, and DNP. The lower panel
provides representative tracings of inner membrane potential from
mitochondria from untreated (blue line) and amobarbital-treated
(red line) hearts.

The improved inner membrane potential following amobarbital treatment suggests that treatment decreases MPTP
opening during reperfusion. However, amobarbital treatment does not improve mitochondrial calcium tolerance
(calcium retention capacity—CRC), another common index
used to reflect MPTP [21, 56]. These results indicate that the
mechanism by which amobarbital treatment decreases inner
mitochondrial membrane permeability is not solely through
prevention of MPTP opening. Cardiolipin is a unique phospholipid located in the inner membrane [48, 57, 58], and
insuﬃcient cardiolipin content or the presence of oxidized
cardiolipin increases inner membrane permeability [59, 60].
Aging does not alter cardiolipin content [61] but results in
the enhanced formation of oxidized cardiolipin species in
both SSM and IFM following ischemia compared to adult
hearts [49]. The increases in oxidized cardiolipin content
persist during reperfusion in the aged heart [49], suggesting ongoing production during the oxidative stress
of reperfusion. Amobarbital treatment during reperfusion

Figure 5: Mitochondrial inner membrane potential following
ischemia-reperfusion. Amobarbital treatment during reperfusion
improved inner mitochondrial potential measured following 30
minutes of reperfusion in both SSM (a) and IFM (b) in the presence
of ADP (ψ 1), oligomycin (ψ 2), and DNP (ψ 3). ψ 1–3 conditions
are as shown in Figure 4. (Mean ± SEM; ∗ P < 0.05 versus untreated
n = 10 in each group.)

may decrease the permeability of the inner membrane by
attenuating the ongoing production of oxidized cardiolipin
during reperfusion. This concept is an area of ongoing study
in our laboratory.
The burst of ROS formation at the onset of reperfusion contributes to myocardial injury [22]. The ischemiadamaged electron transport chain increases the generation
of ROS during reoxygenation in isolated mitochondria
[62]. Protection of mitochondrial electron transport during
ischemia decreases ROS generation during reperfusion [35,
36]. In the present study, amobarbital given during early
reperfusion decreases ROS generation from isolated mitochondria obtained from the aged heart, suggesting that amobarbital decreases myocardial injury by decreasing ROS formation during reperfusion, perhaps leading to decreased
production of oxidized cardiolipin and thereby protecting
the inner mitochondrial membrane. Ischemia increases ROS
generation from complex I and complex III [62]. In the
present study, amobarbital treatment at the onset of reperfusion was likely protective by two complimentary mechanisms. First, amobarbital decreased electron flow into complex III, which produces increased oxidative injury from both
age-related [14–16] and ischemia-induced [35] defects, the
latter observed online in the intact heart [18]. Second, amobarbital treatment decreases complex-I-mediated complex I
damage [19, 35] with decreased production of ROS from

CRC calcium (nM/mg protein)
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Figure 6: Measurement of mitochondrial calcium tolerance. Succinate (10 mM) was used to energize mitochondria. The upper panel
(a) is an original tracing of calcium retention capacity (CRC). A
calcium pulse (20 nmoles) was added each time. The release of
calcium from mitochondria reflected opening of the permeability
transition pore. The lower panel (b) shows that amobarbital
treatment during reperfusion did not improve calcium tolerance in
SSM and IFM compared to mitochondria from untreated hearts.
(Mean ± SEM. P = NS versus untreated n = 10 in each group.)

H2 O2 (pmol/min/mg protein)

complex I as observed during reperfusion in the current
study.
Reperfusion in clinical settings usually occurs following
at least moderate periods of ischemia that result in mitochondrial damage. Transient interruption of mitochondrial
oxidative metabolism only during early reperfusion decreases
myocardial injury in aged hearts providing a relevant approach to limit myocardial cell death during reperfusion in
the high-risk elderly population.
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Figure 7: The generation of reactive oxygen species in mitochondria following ischemia-reperfusion. Amobarbital treatment during
early reperfusion decreased net H2 O2 production in subsarcolemmal mitochondria (SSM) compared to untreated hearts when glutamate was used as a complex I substrate. Amobarbital also tended to
decrease net H2 O2 production in interfibrillar mitochondria (IFM)
compared to untreated hearts (P < 0.06). Data are expressed as
mean ± SEM; ∗ P < 0.05 versus untreated. N = 5 in each group.
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